"uuid:ID","instanceType","rationale","id","versionIdentifier"
"cf555cc6-a48d-421d-b3e4-a5954ce724bf","StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","2"
